Literature DB >> 24060873

Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.

Ryan K Shields1, M Hong Nguyen, Ellen G Press, Cassaundra L Updike, Cornelius J Clancy.   

Abstract

By CLSI interpretive criteria, anidulafungin and micafungin MICs determined by various methods were sensitive (60 to 70%) and highly specific (94 to 100%) for identifying FKS mutations among 120 Candida glabrata isolates. Anidulafungin and micafungin breakpoints were more specific than CLSI's caspofungin breakpoint in identifying FKS mutant strains and patients with invasive candidiasis who were likely to fail echinocandin treatment (P ≤ 0.0001 for both). Echinocandin MICs were most useful clinically when interpreted in the context of prior echinocandin exposure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24060873      PMCID: PMC3837909          DOI: 10.1128/AAC.01451-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

Review 4.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

Authors:  M A Pfaller; D J Diekema; D Andes; M C Arendrup; S D Brown; S R Lockhart; M Motyl; D S Perlin
Journal:  Drug Resist Updat       Date:  2011-02-24       Impact factor: 18.500

5.  EUCAST technical note on anidulafungin.

Authors:  M C Arendrup; J-L Rodriguez-Tudela; C Lass-Flörl; M Cuenca-Estrella; J P Donnelly; W Hope
Journal:  Clin Microbiol Infect       Date:  2011-09-16       Impact factor: 8.067

6.  Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.

Authors:  M A Pfaller; M Castanheira; D J Diekema; S A Messer; G J Moet; R N Jones
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

7.  Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

Authors:  David R Andes; Nasia Safdar; John W Baddley; Geoffrey Playford; Annette C Reboli; John H Rex; Jack D Sobel; Peter G Pappas; Bart Jan Kullberg
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

8.  Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.

Authors:  Nicholas Kartsonis; John Killar; Lori Mixson; Chao-Min Hoe; Carole Sable; Kenneth Bartizal; Mary Motyl
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

9.  Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; R N Jones; J Turnidge; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

10.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

View more
  27 in total

Review 1.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

2.  Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Richard Cumbie; Eileen Driscoll; A William Pasculle; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

3.  Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.

Authors:  Mariana Castanheira; Lalitagauri M Deshpande; Andrew P Davis; Paul R Rhomberg; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

4.  Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy.

Authors:  Ziauddin Khan; Suhail Ahmad; Eiman Mokaddas; Jacques F Meis; Leena Joseph; Aneesa Abdullah; Sandhya Vayalil
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.

Authors:  R H Jensen; H K Johansen; L M Søes; L E Lemming; F S Rosenvinge; L Nielsen; B Olesen; L Kristensen; E Dzajic; K M T Astvad; M C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

6.  Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.

Authors:  Gregory A Eschenauer; M Hong Nguyen; Shmuel Shoham; Jose A Vazquez; Arthur J Morris; William A Pasculle; Christine J Kubin; Kenneth P Klinker; Peggy L Carver; Kimberly E Hanson; Sharon Chen; Simon W Lam; Brian A Potoski; Lloyd G Clarke; Ryan K Shields; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

Review 7.  Echinocandin Resistance in Candida Species: a Review of Recent Developments.

Authors:  Nathan P Wiederhold
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

8.  Epidemiology of echinocandin resistance in Candida.

Authors:  Nina T Grossman; Tom M Chiller; Shawn R Lockhart
Journal:  Curr Fungal Infect Rep       Date:  2014-09-21

9.  Absence of Azole or Echinocandin Resistance in Candida glabrata Isolates in India despite Background Prevalence of Strains with Defects in the DNA Mismatch Repair Pathway.

Authors:  Ashutosh Singh; Kelley R Healey; Priyanka Yadav; Gargi Upadhyaya; Neelam Sachdeva; Smita Sarma; Anil Kumar; Bansidhar Tarai; David S Perlin; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

10.  Abdominal candidiasis is a hidden reservoir of echinocandin resistance.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.